Novavax says its vaccine is 80% effective in teens, but manufacturing questions continue to cloud future

Novavax finally submitted an application for emergency use authorization for its Covid-19 vaccine late last month. Now a second application may already be in the offing.

The oft-delayed but never-boring Maryland-based vaccine company announced positive results from its adolescent trial on Thursday. The biotech’s vaccine, known as Nuvaxovid, was 80% effective at preventing symptomatic disease in patients 12 to 17 years old.